Recent News

• 06.01.2026 - GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
• 05.22.2026 - 8-K - Current report
• 05.15.2026 - 10-Q - Quarterly report [Sections 13 or 15(d)]
• 05.15.2026 - GT Biopharma Reports First Quarter 2026 Financial Results
• 05.14.2026 - GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
• 05.14.2026 - EFFECT - Notice of Effectiveness
• 05.13.2026 - 424B3 - Prospectus [Rule 424(b)(3)]
• 05.06.2026 - CORRESP - Correspondence
• 05.06.2026 - UPLOAD - SEC-generated letter
• 04.30.2026 - S-1 - General form for registration of securities under the Securities Act of 1933

Recent Filings

• 05.22.2026 - 8-K Current report
• 05.15.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 05.13.2026 - EFFECT Notice of Effectiveness
• 04.30.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 04.07.2026 - 8-K Current report